Table 2 Changes in parameters in response to SGLT2 inhibitor administration

BMI (kg/m²)

28.3 (26.1, 31.6)

21

28.0 (26.0, 32.3)

21

27.5 (25.0, 29.9)

**

21

Systolic BP (mmHg)

131.7 ± 14.6

21

127.6 ± 12.0

21

125.4 ± 15.0

21

Diastolic BP (mmHg)

81.9 ± 10.0

21

78.7 ± 8.2

21

76.2 ± 9.4

*

21

HbA1c (%)

6.60 (6.50, 7.10)

21

6.50 (6.40, 6.90)

*

21

6.50 (6.30, 6.80)

*

21

HOMA-R

3.1 (2.6, 5.6)

18

3.7 (2.8, 5.1)

20

3.9 (2.4, 9.8)

18

Hb (g/dL)

14.4 (13.3, 15.3)

19

14.6 (13.7, 15.5)

*

20

14.7 (13.9, 15.7)

*

21

ACR (mg/g Cr)

174.1 (24.3, 794.8)

21

136.0 (15.6, 268.0)

**

21

121.1 (24.5, 288.0)

21

eGFR (ml/min/1.73m²)

62.6 (48.4, 74.4)

21

60.4 (48.0, 74.9)

21

61.1 (45.7, 75.8)

21

NTpro-BNP (pg/mL)

39.0 (15.0, 91.0)

17

53.0 (22.5, 72.5)

20

29.0 (16.5, 47.5)

19

FENa (%)

0.89 ± 0.58

20

0.94 ± 0.61

21

1.03 ± 0.74

21

Uric acid (mg/dL)

6.40 ± 1.08

21

5.48 ± 1.35

**

21

5.57 ± 0.96

**

21

FEUA (%)

5.21 ± 2.49

20

7.03 ± 2.63

**

21

7.12 ± 2.11

**

21

Urine L-FABP/Cr (μg/g Cr)

3.83 (2.66, 6.23)

20

2.40 (1.79, 4.77)

12

2.86 (1.88, 4.08)

21

Urine NAG/Cr (U/g Cr)

7.87 (6.22, 9.96)

19

8.95 (6.30, 12.60)

20

9.04 (5.80, 12.61)

20

Urine MCP-1/Cr (pg/g Cr)

1.83 (1.10, 2.41)

19

2.34 (1.54, 3.06)

21

2.13 (1.76, 3.32)

20

Urine iPF2α-III/Cr (pg/mg Cr)

236.0 (194.5, 285.0)

20

258.0 (170.0, 358.0)

21

255.5 (212.0, 388.0)

20